Latest news with #Wegovy
Economic Times
11 minutes ago
- Health
- Economic Times
ET Graphics: Weight loss drugs Tirzepatide, Semaglutide dominate India, misuse fears rise
Tirzepatide and semaglutide dominate India's anti-obesity drug market, holding a 75% share. While seen as vital tools by doctors, experts caution against misuse, particularly among young adults. Aggressive marketing and social media trends are fueling peer pressure, potentially leading to inappropriate use of these weight-loss medications. Tired of too many ads? Remove Ads New-age weight-loss molecules have taken over the anti-obesity drug market in India , with tirzepatide and semaglutide (generic names) collectively occupying 75% of the market see Eli Lilly's Mounjaro and Novo Nordisk's Wegovy as important ammunitions in the anti-obesity experts also point out the risk of the drug being misused by many — especially young adults — amplied by aggressive marketing, widespread social media promotions and a growing peer pressure driven by the weight loss fad.
Yahoo
25 minutes ago
- Business
- Yahoo
WeightWatchers Returns With a Plan for the New GLP-1 World
WeightWatchers is no longer content to stew about its seemingly slender prospects in the Wegovy era. After the GLP-1 onslaught plunged the company into Chapter 11 submission in May, the dieting brand emerged from bankruptcy last week to announce it had successfully trimmed the fat from its considerable debt load, built a strategy for success moving forward, and plans to relist on the Nasdaq. READ ALSO: Bitcoin Tops $120,000 With Congress Poised to Consider Key Crypto Bills and Inflation Data and Bank Earnings Kick Off a Crucial Test for Markets It's worth remembering that the company, which rebranded as WW International in 2019, was already in trouble before a little weekly injectable came along that promised the same results as being a WeightWatchers client without the arduous processes of carefully scheduled workout classes and calorie-counted meals. The pandemic had already crushed its in-person business, and business never recovered. In 2018, the company reported annual revenue of $1.5 billion; by 2021, that had fallen to $1.2 billion, and by 2024, a measly $800 million. By May, company lawyers proclaimed in a bankruptcy hearing that an 'evolution in consumer preferences and the rapid rise of GLP-1s' made it unable to service its $1.6 billion debt load. Now? WeightWatchers wants to turn GLP-1s from poison pill to bottom line miracle drug, among other plans to rev up new revenue: The company has struck a deal with Novo Nordisk to sell weight loss drug Wegovy directly to clients on its online platform at $299 per month. WeightWatchers set the stage for such a movie in 2023 when it acquired telehealth company Sequence for $132 million. The company also plans to push into menopause treatment plans, which it says is designed to address a broader gap in healthcare. 'It is a very natural overlap. In the perimenopausal and menopausal phase, up to 70% of women experience weight gain,' newly hired Chief Medical Officer Dr. Kim Boyd told Reuters last week. The Ringer: The company will also have help from someone who knows the GLP-1 industry with great intimacy. As it emerges from bankruptcy, WeightWatchers has appointed a new board of directors — among them former Eli Lilly president Mike Mason, who helped pioneer the GLP-1 industry. 'As medical treatments like GLP-1s become more widely used, the need for trusted, comprehensive care models that combine medication with lasting lifestyle change has never been greater,' Mason said in a statement. This post first appeared on The Daily Upside. To receive delivering razor sharp analysis and perspective on all things finance, economics, and markets, subscribe to our free The Daily Upside newsletter. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Time of India
40 minutes ago
- Health
- Time of India
ET Graphics: Weight loss drugs Tirzepatide, Semaglutide dominate India, misuse fears rise
New-age weight-loss molecules have taken over the anti-obesity drug market in India , with tirzepatide and semaglutide (generic names) collectively occupying 75% of the market share. Doctors see Eli Lilly's Mounjaro and Novo Nordisk's Wegovy as important ammunitions in the anti-obesity treatment. However, experts also point out the risk of the drug being misused by many — especially young adults — amplied by aggressive marketing, widespread social media promotions and a growing peer pressure driven by the weight loss fad. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Discover Effortless Glucose Monitoring: Request a Free Trial Dexcom Click Here Undo
Yahoo
an hour ago
- Health
- Yahoo
Weight loss jabs such as Mounjaro linked to lower dementia and stroke risk
Weight loss jabs may offer a protective effect against dementia and stroke, according to a new study. Academics said the benefits of drugs such as Wegovy and Mounjaro – including for managing weight and blood sugar levels – are well known, but other health benefits of the popular drugs remain 'unclear'. People with type 2 diabetes and obesity who are taking the drugs are also less likely to die prematurely, researchers found. The study saw experts from Taiwan examine date on 60,000 people from around the world, with an average age of 58, who had type 2 diabetes and obesity. Key differences between three weight-loss injections: Mounjaro, Wegovy, and Ozempic. — Paul Wischmeyer MD (@Paul_Wischmeyer) July 4, 2025 Around half were given GLP agonist drugs semaglutide and tirzepatide – which are sold under the brand names Wegovy and Mounjaro. Semaglutide is also the main ingredient for the type 2 diabetes drug Ozempic. GLP agonists can reduce a person's appetite; slow down their digestion; reduce the amount of sugar the liver makes and they help the body to make more insulin when needed. The other half used other anti-diabetic medication. 📢Important update Eligible people in #Dorset will be able to access Tirzepatide (Mounjaro) weight management medication from autumn 2025. ✅Around 1,000 people in Dorset will qualify under strict national criteria ✅No need to contact your doctor More: — NHS Dorset (@NHSDorset) June 23, 2025 During a seven-year follow-up period, researchers found that people given the GLP agonist drugs appeared to have a 37% lower risk of dementia and a 19% reduced risk of stroke. They were also 30% less likely to die during the follow-up period. And when researchers looked at the data further they found even greater benefits in people aged 60 or older, women, and those with a body mass index score of 30 to 40. They found no differences in Parkinson's disease or brain bleeds. The academics said their findings suggest 'potential neuroprotective and cerebrovascular benefits' of the drugs but they called for more studies to confirm the findings. Recommended reading: Mounjaro sales adverts banned by watchdog Mounjaro patients report unexpected side-effect Who is eligible for free Mounjaro on the NHS? 'These findings suggest that semaglutide and tirzepatide may offer neuroprotective and cerebrovascular benefits beyond glycemic control, potentially improving long-term cognitive and survival outcomes in adults with type 2 diabetes and obesity,' they wrote in the journal JAMA Network Open. Commenting on the study, Professor Tara Spires-Jones, director of the Centre for Discovery Brain Sciences at the University of Edinburgh and group leader in the UK Dementia Research Institute, said: 'This is a very interesting study adding to evidence that GLP1 receptor agonists are associated with a lower risk of dementia in people with type 2 diabetes and obesity. 'This type of study cannot determine whether the drugs reduced disease risk by directly protecting the brain. 'It is highly likely that effectively treating type 2 diabetes and obesity would reduce dementia and stroke risk as they are known risk factors for these conditions. 'Further work is needed including randomised clinical trials to confirm these drugs are protective in people with diabetes and obesity and other trials are needed to determine whether these drugs will be protective in people who do not have type 2 diabetes and obesity.' Recommended reading: When will Mounjaro be rolled out on the NHS? Travel insurance warning about certain types of policy Warning as Mounjaro and Ozempic sold without prescription Dr Richard Oakley, associate director of research and innovation at Alzheimer's Society, said: 'It is well established that diabetes and obesity can increase your risk of developing dementia. 'This study supports existing evidence that shows these drugs may reduce dementia risk, particularly for people aged 60 and over who are living with type 2 diabetes and obesity. 'Although interesting, we can't draw conclusions from this study alone as it is an observational study, only a small number of people who took part went on to develop dementia and as the impact of these drugs on different types of dementia is not clear. 'There are clinical trials currently looking at whether drugs like these can be used to treat early-stage Alzheimer's disease, so this is a really exciting area being explored in the research fight against dementia.'
The Independent
2 hours ago
- Health
- The Independent
How weight-loss jabs could help lower dementia risk
New research indicates that weight-loss injections, including popular drugs like Wegovy and Mounjaro, may offer protection against serious conditions such as dementia and stroke. The study also suggests that individuals with type 2 diabetes and obesity prescribed these medications could face a reduced risk of premature death. Experts from Taiwan conducted a comprehensive study, examining data from 60,000 people worldwide with an average age of 58, all diagnosed with type 2 diabetes and obesity. During a seven-year follow-up, participants given GLP agonist drugs showed a 37 per cent lower risk of dementia, a 19 per cent reduced risk of stroke, and were 30 per cent less likely to die. Academics noted potential neuroprotective and cerebrovascular benefits but called for more studies, including randomised clinical trials, to confirm these findings.
